Physician profile
Tonya E Anderson
NPI 1750794723
$4,172.49
in general payments reported to CMS, 2019-2025
25 companies · $703 in 2025
The $703 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $801 · 2022: $858 · 2023: $1,073 · 2024: $738 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,251.69 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $793.12 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $518.13 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $508.24 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $232.79 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $231.64 | 2021-2024 | Dexcom G6 Transmitter |
| Corium, LLC | $105.48 | 2023-2025 | Azstarys |
| Glaxosmithkline, LLC. | $99.90 | 2023 | Shingrix |
| Otsuka America Pharmaceutical, INC. | $71.24 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $47.34 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $32.57 | 2021 | |
| Esperion Therapeutics, INC. | $31.99 | 2021-2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $26.53 | 2022-2023 | Trintellix |
| Biogen, INC. | $24.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.21 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $21.73 | 2025 | Qutenza |
| Amgen INC. | $20.22 | 2023 | Repatha, Otezla |
| Pfizer INC. | $18.93 | 2021 | |
| Sanofi Pasteur INC. | $18.72 | 2025 | |
| Paratek Pharmaceuticals, INC. | $16.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.67 | 2021 | |
| Merck Sharp & Dohme LLC | $16.53 | 2021 | |
| Exact Sciences Corporation | $16.23 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $14.08 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.